Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Express Scripts
Baxter
Colorcon
AstraZeneca

Last Updated: May 27, 2022

ADASUVE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch® Generic Entry Outlook for Adasuve

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for ADASUVE
Drug Prices for ADASUVE

See drug prices for ADASUVE

Recent Clinical Trials for ADASUVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lee's Pharmaceutical LimitedPhase 3
University of ArkansasPhase 4
Mount Sinai Hospital, ChicagoPhase 4

See all ADASUVE clinical trials

US Patents and Regulatory Information for ADASUVE

ADASUVE is protected by seven US patents.

Patents protecting ADASUVE

Delivery of antipsychotics through an inhalation route
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method and apparatus for vaporizing a compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method of forming an aerosol for inhalation delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method of forming an aerosol for inhalation delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADASUVE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ADASUVE

See the table below for patents covering ADASUVE around the world.

Country Patent Number Title Estimated Expiration
Australia 2002311923 See Plans and Pricing
Hungary 0401008 AN AEROSOL FORMING DEVICE FOR USE IN INHALATION THERAPY See Plans and Pricing
China 101623528 Method and apparatus for vaporizing a compound See Plans and Pricing
Hong Kong 1129077 用於汽化化合物的方法 (METHOD FOR VAPORIZING A COMPOUND) See Plans and Pricing
Germany 60239604 See Plans and Pricing
Japan 2005525178 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ADASUVE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 CR 2013 00046 Denmark See Plans and Pricing PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098 C01389098/01 Switzerland See Plans and Pricing PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016
1389098 2013C/054 Belgium See Plans and Pricing PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225
1389098 CA 2013 00046 Denmark See Plans and Pricing PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098 SPC/GB13/055 United Kingdom See Plans and Pricing PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220
1389098 300609 Netherlands See Plans and Pricing PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
McKesson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.